Clinical Trial Update: Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for transcranial photobiomodulation being investigated in Alzheimer's disease and mild cognitive impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Transcranial Photobiomodulation

Snippet

Sponsor: NYU Langone Health | Conditions: Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING